ResMedRMD
Market Cap: $36B
About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Employees: 10,140
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
83% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 63
28% more repeat investments, than reductions
Existing positions increased: 301 | Existing positions reduced: 235
7% more funds holding
Funds holding: 700 [Q1] → 752 (+52) [Q2]
2.04% more ownership
Funds ownership: 56.62% [Q1] → 58.66% (+2.04%) [Q2]
0% more capital invested
Capital invested by funds: $16.5B [Q1] → $16.5B (+$12.9M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
34% less call options, than puts
Call options by funds: $178M | Put options by funds: $270M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target | 4%downside $236 | Hold Downgraded | 4 Sept 2024 |
RBC Capital Craig Wong-Pan 0 / 0 met price target | 16%downside $206 | Sector Perform Maintained | 2 Aug 2024 |
Keybanc Brett Fishbin 87% 1-year accuracy 13 / 15 met price target | 3%upside $251 | Overweight Maintained | 2 Aug 2024 |
Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target | 4%downside $236 | Buy Reiterated | 2 Aug 2024 |
RBC Capital Craig Wong-Pan 0 / 0 met price target | 17%downside $204 | Sector Perform Maintained | 23 Jul 2024 |
Financial journalist opinion
Based on 10 articles about RMD published over the past 30 days